administrative, legislative, and program developments in the drug abuse field. Attendance by the public will be limited to space available.

On September 20, from 9 a.m. to 1 p.m., the meeting will be held at the Parklawn Building, Conference Room E, 5600 Fishers Lane, Rockville, MD 20857. In accordance with provisions set forth in section 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. and section 10(d) of Pub. L. 92-463, this portion of the meeting will be closed to the public for the review, discussion, and evaluation of grant applications. These applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

A summary of the meeting and a roster of committee members may be obtained from Ms. Camilla L. Holland, NIDA Committee Management Officer, National Institutes of Health, Parklawn Building, Room 10–42, 5600 Fishers Lane, Rockville, Maryland 20857 (301/443–2755).

Substantive program information may be obtained from Ms. Eleanor C. Friedenberg, Room 10–42, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857, (301/443–2755).

Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the contact person named above in advance of the meeting. (Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Research Scientist Development and Research Scientist Development and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs) Dated: August 8, 1995.

Susan K. Feldman,

Committee Management Officer, NIH. [FR Doc. 95–20043 Filed 8–14–95; 8:45 am] BILLING CODE 4140–01–M

#### National Institutes Of Health

### Prospective Grant of Exclusive License: Immunologic Enhancement With Intermittent Interleukin-2 Therapy

AGENCY: National Institutes of Health, Public Health Service, DHHS. ACTION: Notice.

**SUMMARY:** This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Application SN 08/063,315 (U.S. Patent 5,419,900) entitled "Immunologic Enhancement with Intermittent Interleukin-2 Therapy" and related U.S. and foreign patent applications to Chiron Corporation of Emeryville, CA. The patent rights in this invention have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. It is anticipated that this license may be limited to all therapeutic applications including treatment of HIV infection and AIDS. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent application describes the continuous intermittent infusion of interleukin-2, alone or in combination with retroviral therapy, into a patient as a means of enhancing the patient's immune system. The ability of this therapy to stimulate immune function may have advantages in any disease state in which interleukin-2 plays a role in the associated immune response, and may therefore be useful in the treatment of HIV infections and AIDS, as well as for the attendant opportunistic infections that occur in AIDS patients.

ADDRESSES: Requests for a copy of this patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Steven M. Ferguson, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852. Telephone: (301) 496–7735; Facsimile: (301) 402-0220; E-mail: Steve-Ferguson@NIH.GOV. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before October 16, 1995, will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. A signed Confidential Disclosure

Agreement will be required to receive a copy of the patent application.

Dated: August 2, 1995.

#### Barbara M. McGarey,

Deputy Director, Office of Technology Transfer. [FR Doc. 95–20044 Filed 8–14–95; 8:45 am] BILLING CODE 4140–01–P

# DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

## Office of Administration

[Docket No. FR-3917-N-16]

# Notice of Submission of Proposed Information Collection to OMB

**AGENCY:** Office of Administration, HUD. **ACTION:** Notice.

**SUMMARY:** The proposed information collection requirement described below has been submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments must be received within thirty (3) days from the date of this Notice. Comments should refer to the proposal by name and should be sent to: Joseph F. Lackey, Jr., OMB Desk Officer, Office of Management and Budget, New Executive Office Building, Washington, DC 20503.

**FOR FURTHER INFORMATION CONTACT:** Kay F. weaver, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, Southwest, Washington, DC 20410, telephone (202) 708–0050. This is not a toll-free number. Copies of the proposed forms and other available documents submitted to OMB may be obtained from Ms. Weaver.

**SUPPLEMENTARY INFORMATION:** The Department has submitted the proposal for the collection of information, as described below, to OMB for review, as required by the Paperwork Reduction Act (44 U.S.C. Chapter 35).

The Notice lists the following information: (1) the title of the information collection proposal; (2) the office of the agency to collect the information; (3) the description of the need for the information and its proposed use; (4) the agency form number, if applicable; (5) what members of the public will be affected by the proposal; (6) an estimate of the total number of hours needed to prepare the